« Back
Home /
Olcegepant

Olcegepant

€59.00

Excl. VAT

Item no.	HY-10095-2mg
Manufacturer	MedChem Express
CASRN	204697-65-4
Amount	2 mg
Category	Oncology Neuroscience Neural Lineage Markers Targets for Rodent Neurosciences Aging & Neurological Disorders Neural Signaling Inhibitors & Compound Libraries Small Molecules By Organ Thyroid Cancer Neuronal Cell Markers
Type	Inhibitors
Specific against	other
Purity	99.50
Formula	C38H47Br2N9O5
Citations	Biomed Res Int. 2022 Jun 16;2022:1585840. Cell Physiol Biochem. 2017;41(4):1457-1467. Department of Biology, Chemistry, Pharmacy. 2020 Oct. Freie Universitt Berlin. 2021 Feb. Front Cell Neurosci. 2018 Sep 11;12:304. Int Endod J. 2023 Oct 24. Int J Mol Sci. 2019 Nov 20;20(23):5826. J Headache Pain. 2022 Sep 30;23(1):128. J Invest Dermatol. 2019 Mar;139(3):656-664. Korean J Pain. 2022 Apr 1;35(2):173-182. Nat Med. 2016 Oct;22(10):1160-1169. Neuropeptides. 2015 Aug;52:31-7. Orthop J Sports Med. July 13, 2021. Peptides. 2021 Jan;135:170423. Research Square Print. August 19th, 2022. Sci Rep. 2020 Jul 10;10(1):11408. Sci Rep. 2022 Aug 16;12(1):13894. Vascul Pharmacol. 2017 Mar;90:36-43. Adv Sci (Weinh). 2021 Oct 28;e2103005. Cephalalgia. 2020 Aug;40(9):924-934. Cephalalgia. 2021 Mar;41(3):329-339. Cephalalgia. 2019 Dec;39(14):1827-1837. J Headache Pain. 2022 Mar 8;23(1):35. Journal of Traditional Chinese Medical Sciences. 21 June 2022. Sci Rep. 2018 Jan 30;8(1):1836. [1]Sixt ML, et al. Calcitonin gene-related peptide receptor antagonist Olcegepant acts in the spinal trigeminal nucleus. Brain. 2009 Nov;132(Pt 11):3134-41. [2]Michot B, et al. Differential effects of calcitonin gene-related peptide receptor blockade by Olcegepant on mechanical allodynia induced by ligation of the infraorbital nerve vs the sciatic nerve in the rat. Pain. 2012 Sep;153(9):1939-48. [3]Rudolf K, et al. Development of human calcitonin gene-related peptide (CGRP) receptor antagonists. 1. Potent and selective small molecule CGRP antagonists. 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-l-lysyl]-4-(4-pyridinyl)piperazine: the first CGRP antagonist for clinical trials in acute migraine. J Med Chem. 2005 Sep 22;48(19):5921-31. [4]Doods H, et al. Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist. Br J Pharmacol. 2000 Feb;129(3):420-3. [5]Edvinsson L, et al. Effect of the CGRP receptor antagonist BIBN4096BS in human cerebral, coronary and omentalarteries and in SK-N-MC cells. Eur J Pharmacol. 2002 Jan 2;434(1-2):49-53.
Smiles	O=C1N(CC2=C(N1)C=CC=C2)C3CCN(C(N[C@@H](C(N[C@H](C(N4CCN(C5=CC=NC=C5)CC4)=O)CCCCN)=O)CC6=CC(Br)=C(C(Br)=C6)O)=O)CC3
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	BIBN-4096; BIBN 4096BS
Available
Product Description	Olcegepant (BIBN-4096) is a potent and selective non-peptide antagonist of the calcitonin gene-related peptide 1 (CGRP1) receptor with IC50 of 0.03 nM and Ki of 14.4 pM for human CGRP[1][2].
StorageTemperature	-20°C, 3 years; 4°C, 2 years (Powder)
Shipping	Room Temperature
Manufacturers Applications	Neuroscience-Neuromodulation
Molecular Weight	869.65
Clinical Information	Phase 2
Solubility	1M HCl : 50 mg/mL (ultrasonic; adjust pH to 1 with HCl)\|DMSO : ≥ 50 mg/mL
Pathway	GPCR/G Protein; Neuronal Signaling
Manufacturers Product type	Reference compound

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-10095-2mg-safety-datasheet.pdf